Subject: Consent Agenda: Board and committee nominations

Report of: Debbie Adams, Managing Director, Law and Governance
Authored by: Kevin A. Klock, Head of Governance and Assistant Secretary
Agenda item: 02a
Category: For Decision
Strategic goal: Alliance operations

Section A: Overview

1 Purpose of the report

1.1 This report informs the Board of the Governance Committee’s recommendations for Board and committee membership.

2 Recommendations

2.1 The Governance Committee recommended to the GAVI Alliance Board that it:

(a) **Appoint** the following Board Members:

- **Tim Evans** as Board Member representing the World Bank effective immediately until his successor is appointed.

- **Ruhakana Rugunda** as Board Member representing the developing country constituency in the seat currently held by Christine Ondoa effective immediately until 31 December 2014.

- **Walter Seidel** as Board Member representing the European Commission, France, Germany, Luxembourg donor constituency in the seat currently held by Gustavo Gonzalez-Canali effective immediately until 31 December 2014.

(b) **Reappoint** the following Board Member:

- **Angela Santoni** as Board Member representing the Italy and Spain donor constituency until 31 December 2014.

---

1 Candidate biographies are located in Section B.
(c) **Exceptionally Extend** the terms of the following Board Members:

- **Wayne Berson** as an Unaffiliated Board Member until 31 December 2014.
- **George W. Wellde Jr.** as an Unaffiliated Board Member until 31 December 2014.

(d) **Appoint** the following Alternate Board Members:

- **Shanelle Hall** as Alternate Board Member to Geeta Rao Gupta representing UNICEF in the seat currently held by Nicholas Alipui effective immediately until her successor is appointed.
- **Emmanuel Lebrun-Damiens** as Alternate Board Member to Walter Seidel representing the European Commission, France, Germany, Luxembourg donor constituency in the seat currently held by Walter Seidel effective immediately until 31 December 2014.
- **Beate Stirø** as Alternate Board Member to Anders Nordström representing the Sweden, Netherlands, Denmark, Norway donor constituency in the seat currently held by Paul Fife effective immediately until 31 December 2014.
- **Bheri Ramsaran** as Alternate Board Member to Andrei Usatii representing the developing country constituency in the seat formerly held by María del Socorro Interiano Portillo effective immediately until 31 December 2015.

(e) **Reappoint** the following Alternate Board Members:

- **José Luis Solano** as Alternate Board Member to Angela Santoni representing the Italy and Spain donor constituency until 31 December 2014.
- **Micheline Gilbert** as Alternate Board Member to Donal Brown representing the United Kingdom, Canada, Ireland donor constituency until 1 July 2016.

(f) **Appoint** the following to the Executive Committee effective 1 January 2014:

- Dagfinn Høybråten (statutorily appointed).
- Geeta Rao Gupta (statutorily appointed).
- Wayne Berson until 31 December 2014.
- Flavia Bustreo until 31 December 2015.
- Awa Marie Coll-Seck until 31 December 2015.
- Jenny Da Rin until 31 December 2014.
Report to the GAVI Alliance Board

- Tim Evans until 31 December 2015.
- Ashutosh Garg until 31 December 2014.
- Orin Levine until 31 December 2015.
- George W. Wellde Jr. until 31 December 2014.
- Seth Berkley (non-voting and statutorily appointed).

(g) **Appoint** the following to the Audit and Finance Committee effective 1 January 2014:

- Wayne Berson until 31 December 2014.
- Micheline Gilbert until 31 December 2015.
- Yifei Li until 31 July 2015.
- Tom Hunstad until 31 December 2015.
- Derek Strocher until 31 December 2015.
- Marcus Koll until 31 December 2015.

(h) **Appoint** the following to the Investment Committee effective 1 January 2014:

- Wayne Berson until 31 December 2014.
- Ashutosh Garg until 31 December 2014.
- George W. Wellde Jr. until 31 December 2014.

(i) **Appoint** the following to the Governance Committee effective 1 January 2014:

- Geeta Rao Gupta (statutorily appointed).
- Joan Awunyo-Akaba until 30 June 2015.
- Donal Brown until 31 December 2015.
- Maria C. Freire until 31 July 2015.
- Shanelle Hall until 31 December 2015.
- Orin Levine until 31 December 2015.
- Olga Popova until 31 July 2014.
- Samba O. Sow until 31 December 2015.
- Beate Stirø until 31 December 2014.
• George W. Wellde, Jr. until 31 December 2014.
• Seth Berkley (non-voting) until 31 December 2015.

(j) **Appoint** the following to the Programme and Policy Committee effective 1 January 2014:

• Raj Baisya until 31 December 2015.
• Zulfiqar A. Bhutta until 31 December 2015.
• Rajinder Suri until 31 December 2015.
• Susan McKinney until 31 December 2015.
• Steve Landry until 31 December 2015.
• Emmanuel Lebrun-Damiens until 31 December 2014.
• Lene Lothe until 31 December 2015.
• Clarisse Loe Loumou until 31 December 2015.
• Ahmad Jan Naeem until 31 December 2015.
• Robert Oelrichs until 31 December 2015.
• Jean-Marie Okwo-Bele until 31 December 2015.
• Richard Sezibera until 31 December 2015.
• Klaus Stohr until 31 July 2014.
• Andrei Usatii until 31 December 2015.
• Jos Vandelaer until 31 December 2015.
• Seth Berkley (non-voting) until 31 December 2015.

(k) **Reappoint** the following to the Evaluation Advisory Committee:

• Sania Nishtar until 31 December 2014.
• Angela Santoni until 31 December 2014.
• Samba O. Sow until 31 December 2015.
• Naveen Thacker until 30 June 2015.

2.2 The minutes will note that Board members who are candidates for these positions, or whose organisations or constituencies provided candidates for these positions, did not participate in discussion or voting on those nominations.
3 Executive summary

Notification

3.1 On 9 April 2013, the Secretary circulated a note reminding Board members that Board and Committee nominations would be due on 14 October. The Board Chair circulated a similar note on 5 August. Finally, the Secretary circulated a note on 15 October extending the deadline to 24 October 2013.

Length of Committee terms

3.2 In June 2013, the Board extended the terms for which Committee members could be appointed to two years. Two year terms are therefore incorporated in the recommendations unless the particular Board member’s term is ending prior to that or unless they otherwise request.

Constituency processes

3.3 Board members representing eligible organisations (WHO, UNICEF, World Bank, Bill & Melinda Gates Foundation) serve until their organisations inform GAVI that they would like to change them. On 17 July 2013, the World Bank informed the Secretariat that Tim Evans would take over the Board seat. In addition, on 20 October 2013, UNICEF informed the Board Chair that Shanelle Hall would take over the alternate Board seat.

3.4 In March 2013, the Governance Committee noted the following with regard to the unaffiliated Board members: “Given prior discussions at the Executive Committee in September 2012, and a desire to ensure that the Board does not lose the institutional memory of long-standing unaffiliated members, as well as a desire to ensure overlap of existing unaffiliated Board members and new appointments, the Chair asked the Governance Committee to consider approving and taking forward the recruitment subcommittee’s recommendation that the terms of Wayne Berson and George W. Wellde Jr to the GAVI Alliance Board be extended, if necessary in a staggered fashion.” The Governance Committee agreed and recommended extending their terms to the end of 2014.

3.5 In a meeting in Brazzaville, Republic of Congo on 3 September 2013, the GAVI-eligible countries in Anglophone Africa discussed a number of pertinent GAVI issues including their representation on the Board. They reported that the “members of the meeting enthusiastically agreed that Honorable Dr Ruhakana Rugunda, Minister of Health of Uganda, should represent the Anglophone Africa countries.”

3.6 The GAVI-eligible countries in the EURO/AMRO constituency have agreed to submit a representative from one region to serve as Board member and a representative from the other region to serve as alternate Board member, and then they rotate. The incumbent alternate Board member from the AMRO region resigned early and so a new alternate Board member from the AMRO region was sought. In submitting a new
candidate, GAVI-eligible countries in the AMRO region noted that “representation before the GAVI Board on behalf of the poorer countries of Latin America and the Caribbean continues to be a priority of their Governments, aimed at ensuring that the gains made in their vaccination programmes are not threatened or reversed.” With this in mind, during the meeting of the Directing Council of PAHO held between 30 September and 4 October 2013, Minister Ramsaran of Guyana was nominated to serve as alternate Board member.

3.7 In June 2012, GAVI’s donors agreed in principle to formalise the operations of the constituencies and submitted a paper that outlined the principles to guide constituencies and the responsibilities of the lead convening donor. One of the principles was that the rotation of positions within the constituency should be in accordance with an agreed policy or schedule developed by the constituency. Where possible this rotation should align with the GAVI governance calendar for renominating committees.

(a) **Italy and Spain:** On 9 October, Italy informed the Secretariat that the incumbent Board member and alternate Board member should be renewed. Spain also notified the Secretariat of this intention on 16 October.

(b) **France, EC, Germany, Luxembourg:** On 18 September, the constituency informed the Board Chair that it agreed to rotate its seat among the constituency members on an annual basis, with the alternate Board member being nominated as Board member for the subsequent year. As such, the current alternate Board member, Walter Seidel, has been forwarded as Board member for 2014. Emmanuel Lebrun-Damiens, who is being forwarded as alternate Board member for 2014, would be forwarded next year for Board member in 2015. Of note, the constituency submitted the following with regard to the gender policy: “As we do not have an overview of the gender balance in other nominations, we cannot assess in which way we contribute to the overall picture. We assure you however that we have very carefully examined the possibility of nominating female members for 2014 (a major reason why we reply late to your mail), but have failed to identify sufficiently senior candidates, all possible candidates being currently fully engaged in other Boards or other senior positions, and therefore unable to take this additional burden.”

(c) **Norway, Denmark, Netherlands, Sweden:** On 10 September, Norway confirmed that after a discussion of the constituency, it had decided to designate Beate Stirø as an alternate Board member. She will take over for Paul Fife who asked to convey his appreciation for all the support and encouragement received from his GAVI colleagues.

(d) **United Kingdom, Canada, Ireland:** On 15 October, the constituency confirmed that Micheline Gilbert would continue to serve as alternate Board member. Her term will now align with Donal Brown’s term as Board member.
3.8 The industrialised country vaccine industry is represented by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). The constituency reported that the incumbent Board member and alternate Board member should be renewed but that during the summer of 2014, there was likely to be rotation of these members.

4 Risk implication and mitigation

4.1 There is capacity risk for the Board if recommended candidates are not appointed and empty seats are not quickly filled after terms expire.

5 Financial implications: Business plan and budgets

5.1 There are no financial implications.

Section B: Board member biographies

6 Board members

6.1 Tim Evans is the Director for Health, Nutrition and Population at the World Bank. Dr. Evans has been active in the international health arena for more than 20 years. Before joining the World Bank he was the Dean of the James P. Grant School of Public Health of BRAC University in Bangladesh. Previously he served as Assistant Director General at the World Health Organization, heading the Evidence, Information, Research and Policy Clusters, where he oversaw the production of the annual World Health Report. Dr. Evans has been a leader in advancing global health equity and health systems performance throughout his career, notably through his work with the Rockefeller Foundation and the Harvard School of Public Health and with his contributions to the development of innovative partnerships, including the Global Alliance on Vaccines and Immunization, INDEPTH and Health Metrics networks, the Global Health Workforce Alliance and the World Alliance for Patient Safety. Dr. Evans earned his DPhil in agricultural economics at Oxford, and pursued medical and postgraduate studies at McMaster and Harvard Universities.

6.2 Ruhakana Rugunda is the current Minister of Health in the Ugandan Cabinet. Prior to that he served as Minister of Information and Communications Technology from May 2011 until May 2013. He also served as Uganda's Permanent Representative at the United Nations, from January 2009 until May 2011. He is a medical doctor and received his training from Makerere University Medical School and later at the University of Zambia where he qualified in Medicine. He has a Masters Degree in Public Health from the University of California, Berkeley. Before joining Ugandan politics, Rugunda worked as Medical Officer in Zambia as a physician, at DC General Hospital in Washington DC and at Kenyatta National Hospital in Nairobi, Kenya. Dr. Rugunda is a carrier Cabinet Minister and has formerly held many Ministerial portfolios' positions in the Ugandan Government including, among others, Minister of Health, Minister of Internal Affairs, Minister of Water & Environment and Minister
of Foreign Affairs. He also sits on the board of directors of the Uganda-based National Bank of Commerce. In July 2006, Rugunda led a Ugandan government negotiating team to Juba, Sudan to hold peace talks with the Lord’s Resistance Army.

6.3 **Walter Seidel** graduated as a physician in 1978, and holds a Master degree in public health (MSc CHDC, LSHTM, 1989) and a doctoral degree on a nutrition subject (University of Giessen, Dr.med., 1992). After initial years in clinical medicine (mainly surgery and obstetrics) in Germany he worked as District Medical Officer in Burkina Faso (with DED, 1982-85), as a health programme manager at a German development agency, at HQ (gtz; 1986-1990) and at country level (gtz; Madagascar 1990-1993). From 1993 to 2001 he was Director of the health department of DSE, a German public development agency dealing with training and dialogue programmes for developing countries. Since 2001 he is working for the European Commission in Brussels, supporting health aid policy development and health programme design and implementation in developing countries, since 2005 as coordinator of the health team.

6.4 **Angela Santoni** is an Immunologist with forty years of experience in biomedical research. She teaches Immunology and Immunopathology at the School of Medicine of the “Sapienza” University of Rome, where she heads the Department of Molecular Medicine. She presently is the Scientific Director of the “Pasteur Institute - Fondazione Cenci Bolognetti” of Rome, a private non-profit foundation specialized in biomedical research. For several years she was a researcher at the Laboratory of Experimental Chemotherapy and Immunodiagnosis, and at the Biological Response Modifiers Program, of NCI-NIH, Bethesda. She is member of several national and international committees, with specific expertise in Molecular Biology. She is a member of several editorial Boards of scientific publications in Europe and the US, author in highly qualified international journals, and guest speaker in several national and international scientific congresses.

6.5 **Johan van Hoof** is Managing Director of Crucell. Formerly, he was Global Therapeutic Area Head, Infectious Diseases & Vaccines, Pharmaceuticals Research & Development, Johnson & Johnson. From November 2007 through March 2010, Dr Van Hoof was Chief Operating Officer - Head, Global Development Organization, JnJ Pharmaceuticals Research & Development. Prior to November 2007, he was Vice President of Global Clinical Operations. Before joining J&J, Mr. Van Hoof acquired more than 20 years of experience in the vaccine industry, having worked with Pasteur Mérieux Connaught (today Sanofi Aventis), Chiron Vaccines and GlaxoSmithKline (GSK) Biologics. During this period, he held leadership roles with increasing responsibilities covering, clinical development, QA-QC, and regulatory affairs. He was actively involved in the development and licensing of a new generation of childhood and adult vaccines in disease areas such as pertussis, meningitis, rotaviral diarrhea, hepatitis, flu and HPV.
6.6 **Wayne Berson** is a Partner and the Chief Executive Officer of BDO USA, LLP. Prior to his election to this position, Mr Berson was BDO’s Presiding Member of the Board, the Mid Atlantic Assurance Regional Managing Partner, the National Director of Not-for-Profit Services, and the Director of the Institute for Nonprofit Excellence. He is a current member of the Global Board of Directors of BDO International, Ltd. and effective January 1, 2014 will serve as its Chairman of the Board. Mr Berson holds accounting degrees from the University of Cape Town and the University of South Africa.

6.7 **George W. Wellde Jr.** is a retired Partner and Vice Chairman of the Securities Division of Goldman, Sachs & Co. He currently serves as a director of Fortress Investment Group. Mr. Wellde holds a BS in Finance from the University of Richmond where he was on the Board of Trustees for ten years, and served as the chair of the Board from 2006 to 2010. In addition, he earned his MBA from George Washington University where he currently serves as a trustee. He is a member of both universities' Investment Committees. Lastly, he serves a board member at the Partnership for Public Service and is a member of the Council on Foreign Relations.

7 **Alternate Board members**

7.1 **Shanelle Hall** is the Director of UNICEF Supply Division, the organization’s procurement and logistics headquarters in Copenhagen. She oversees UNICEF’s global supply activities and emergency supply response, with an annual expenditure approaching US$ 3 billion. She is responsible for both the global availability and local delivery of essential supplies for children in over 150 countries. This is achieved through working with UNICEF programmes, cooperating with governments, and coordinating with UN agencies and other partners. Prior to joining UNICEF, she worked for nine years in the private sector in the area of energy infrastructure development in a number of countries. She is a US national from Seattle, Washington.

7.2 **Emmanuel Lebrun-Damiens** is Assistant Director for Health, Food Security and Human Development at the French Ministry of Foreign Affairs. He served as a diplomat at Headquarters in Paris (Financial affairs, Development and Management of Global Public Goods) and abroad (Deputy Head of Mission at the Embassy of France in New Zealand from 2005 to 2008, Negotiator on Humanitarian Affairs and Health in the Permanent Representation of France to the United Nations in New York from 2008 to 2011). He is a graduate of the Political Studies Institute of Strasbourg and a former student of the Administration National School (ENA).

7.3 **Beate Stiø** joined the Norwegian Ministry of Foreign Affairs in 1990. She was appointed Policy Director, Global Health Issues in the Section for Climate Change, Global Health and Sustainable Development in August 2013. When posted to the Permanent Mission of Norway in Geneva from
2007 –2013, she was responsible for Norway’s engagement with the Human Rights Council during four years, before taking over the global health portfolio. She then served as a member of UNAIDS Programme Coordinating Board, alternate member of UNITAID Executive Board and assisted the Norwegian membership of WHO Executive Board. She has been posted to the Norwegian Embassy in Buenos Aires (1995-1999) and has handled a broad range of issues while stationed in Oslo. She also attended the Royal Norwegian Defence College in 2007 and holds a Master Degree in Political Science from the University of Oslo.

7.4 **Bheri Ramsaran:** The Minister of Health of Guyana, Dr. Bheri Sygmond Ramsaran, is a recognized leader who has established strong national and regional partnerships within and beyond the health sector. Minister Ramsaran first acceded to high office in the national Ministry of Health in 1996, as Director of Regional Health Services. In 2006, as Minister in the Office of the Minister of Health, or Junior Minister of Health, he aimed at turning around the national health system and reinvigorating international relations for improved results in health cooperation; and in 2011, he became the Minister of Health of Guyana. Dr. Ramsaran has been a Member of Parliament since 1998; and prior to acceding to ministerial responsibilities, he served on the watchdog Public Accounts Committee (PAC) of the Parliament. The Minister of Health of Guyana has also shown leadership within the Caribbean Community. This was reflected in Dr. Ramsaran’s role as Chairman of CARPHA – the emerging Caribbean Public Health Agency – at the critical initial juncture of its formation out of the five pre-existing Caribbean Health Institutions. In the capacity of Junior Minister of Health, he managed the network of Regional Clinical Services (including Indigenous Health and Medical Evacuations and the recent construction of new and expanded Rural and Hinterland Health Infrastructure); oversaw Health Education (including training) and functioned as Health Liaison (with special emphasis on the Joint Government of Guyana/Cuba Joint Commission and expansion of relations with other overseas Centers of Excellence previously not engaged; and representing Guyana at high level Regional and International Fora). Guided and well-considered investments have demonstrated Minister Ramsaran’s leadership and strong commitment to the principle of the right to health and its universal accessibility, especially among the poorer sectors of the population and the Indigenous communities. This has been realized through a policy of no fee for the health services and the strengthening of health infrastructure and systems, coupled with an unprecedented massive expansion of training of its work force along with other comprehensive actions with the aim of bringing “more services, to more people, at more times, in more communities, by more and better qualified care givers”. Guyana consequently has an excellent National Immunization Programme. Guyana seamlessly introduced the PCV-13 vaccine two years ago. The country is now well positioned with its network of improved and dispersed health infrastructure and expanded, trained health personnel to confront the emerging epidemic of NCDs. This transformative work of the Ministry of Health led by Minister Ramsaran greatly supports the efforts of the Government of Guyana in the
promotion of sustained human development, with a strong component of citizen participation, which is permitting noteworthy transformations within different areas of economic, social and cultural activity of the country, with significant impact on the health status of the population especially the poor and Indigenous.

7.5 **José Luis Solano** is a senior diplomat with 33 years of extensive experience in the diplomatic field, including monitoring Spanish cooperation projects. From August 1996, he was Deputy Director General in the Foreign Affairs Office at the press office. He was also Ambassador on Special Mission of Political Reconstruction and Stabilisation in Afghanistan. He has also served as Spain’s Ambassador to Cameroon, the Central African Republic, and Chad, and Lithuania. He holds both a law degree and a diploma of international studies.

7.6 **Olga Popova** is currently the Head of Government Affairs & Global Vaccine Policy in Crucell, based in the Netherlands. She joined Crucell in 2007. Prior to that, Dr Popova gained her vaccinology experience at Novartis Vaccines, starting in 2001 as an Associate Director of Medical Affairs, where she took care of numerous worldwide vaccines projects, covering the fields of influenza, meningitis and rabies. She also headed the Medical Support team, responsible for providing scientific and medical information services for infectious diseases and vaccines. Dr Popova worked for 10 years in the pharmaceutical sector, in a number of clinical development and medical affairs positions based in Europe. Dr Popova holds a dual Russian / Italian citizenship and obtained her medical degree from the University of Moscow in 1992. She is fluent in five languages.

7.7 **Micheline Gilbert** has over 20 years of international development experience in West, Central and South Africa and the Caribbean. She worked in developing countries for 7 years with UNDP (Rwanda, Angola, Cambodia) and 3 years for CIDA in Mozambique. She has experience in international development including analysis, design, implementation, monitoring and evaluation of health programming, including programme budget support and health sector wide approach. She holds a MA in Economics and a graduate degree in international development from the Institute for Development and International Cooperation. Ms Gilbert is currently a Senior Analyst at the Canadian International Development Agency with the Global Initiatives Directorate providing programme and financial support and advice in relation to CIDA’s portfolio on immunization. She currently sits on GAVI’s Audit and Finance Committee.

**Section C: Implications**

8 **Impact on countries**

8.1 Filling seats helps to ensure representation of constituency views.

9 **Impact on GAVI stakeholders**

9.1 Filling seats helps to ensure representation of constituency views.
10  Impact on Secretariat
10.1 There is no impact on the Secretariat.

11  Legal and governance implications
11.1 Governance implications are listed throughout this paper.

12  Consultation
12.1 Governance Committee; Additional consultation is outlined in section 3.

13  Gender implications
13.1 The Board gender guidelines provide for at least a 60-40 gender balance.

**Board members**
13.2 As of 31 October, the Board had 15 men (56%) and 12 women (44%), plus one seat vacant (World Bank).
13.3 If the Board elects all of the candidates, there would be 16 men (59%) and 11 women (41%) with one vacancy (unaffiliated).

**Alternates**
13.4 Of the alternates, there are 14 men (82%) and 3 women (18%), plus one seat vacant (developing country governments).
13.5 If the Board elects all of the candidates, there would be 13 men (72%) and 5 women (28%) with no vacancies.